The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
03 08 2020
Historique:
received: 20 05 2020
accepted: 03 08 2020
pubmed: 4 8 2020
medline: 20 2 2021
entrez: 4 8 2020
Statut: epublish

Résumé

Akt is a critical protein kinase that governs cancer cell growth and metabolism. Akt appears to be autoinhibited by an intramolecular interaction between its N-terminal pleckstrin homology (PH) domain and kinase domain, which is relieved by C-tail phosphorylation, but the precise molecular mechanisms remain elusive. Here, we use a combination of protein semisynthesis, NMR, and enzymological analysis to characterize structural features of the PH domain in its autoinhibited and activated states. We find that Akt autoinhibition depends on the length/flexibility of the PH-kinase linker. We identify a role for a dynamic short segment in the PH domain that appears to regulate autoinhibition and PDK1-catalyzed phosphorylation of Thr308 in the activation loop. We determine that Akt allosteric inhibitor MK2206 drives distinct PH domain structural changes compared to baseline autoinhibited Akt. These results highlight how the conformational plasticity of Akt governs the delicate control of its catalytic properties.

Identifiants

pubmed: 32744507
doi: 10.7554/eLife.59151
pii: 59151
pmc: PMC7438110
doi:
pii:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1

Banques de données

Dryad
['10.5061/dryad.0p2ngf1xg']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : EB002026
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM080189
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA074305
Pays : United States
Organisme : NCI NIH HHS
ID : CA74305
Pays : United States
Organisme : American Heart Association
ID : 19POST34380800
Pays : International
Organisme : Austrian Science Fund FWF
ID : J 3872
Pays : Austria

Informations de copyright

© 2020, Chu et al.

Déclaration de conflit d'intérêts

NC, TV, HB, AS, AB, HA No competing interests declared, PC Senior editor, eLife

Références

Methods Enzymol. 2005;394:483-506
pubmed: 15808234
J Med Chem. 2016 Jul 14;59(13):6455-69
pubmed: 27305487
Biophys J. 2017 Jul 25;113(2):393-401
pubmed: 28746850
Am J Transl Res. 2010 Jan 01;2(1):19-42
pubmed: 20182580
PLoS Biol. 2007 Apr;5(4):e95
pubmed: 17407381
Mol Cell. 2002 Jun;9(6):1227-40
pubmed: 12086620
Elife. 2013 Jul 09;2:e00691
pubmed: 23853711
Clin Cancer Res. 2012 Oct 15;18(20):5816-28
pubmed: 22932669
Oncogene. 2010 Jan 7;29(1):150-5
pubmed: 19802009
Cell. 2018 Aug 9;174(4):897-907.e14
pubmed: 30078705
Proteins. 2005 Jun 1;59(4):687-96
pubmed: 15815974
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3940-E3949
pubmed: 29632185
Biochemistry. 2009 Jul 21;48(28):6624-32
pubmed: 19518076
Mol Cancer Ther. 2010 Jul;9(7):1956-67
pubmed: 20571069
Biochem J. 2003 Nov 1;375(Pt 3):531-8
pubmed: 12964941
J Biomol NMR. 2012 Apr;52(4):315-27
pubmed: 22331404
Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22
pubmed: 20027184
Nat Rev Mol Cell Biol. 2018 Jan;19(1):31-44
pubmed: 28974775
J Med Chem. 2012 Jun 14;55(11):5291-310
pubmed: 22533986
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6705-10
pubmed: 9618476
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12366-71
pubmed: 9356455
Oncogene. 1998 Jul 23;17(3):313-25
pubmed: 9690513
Science. 1991 Aug 9;253(5020):657-61
pubmed: 1871600
Biophys J. 1998 Jul;75(1):422-7
pubmed: 9649402
Semin Cancer Biol. 2018 Feb;48:1-17
pubmed: 28591657
Nature. 2014 Apr 24;508(7497):541-5
pubmed: 24670654
Nat Struct Biol. 2000 Mar;7(3):220-3
pubmed: 10700281
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Curr Opin Struct Biol. 2019 Dec;59:47-53
pubmed: 30901610
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
J Am Chem Soc. 2018 Aug 1;140(30):9374-9378
pubmed: 30016585
Nat Struct Biol. 2000 Mar;7(3):188-9
pubmed: 10700272
PLoS Biol. 2009 Jan 20;7(1):e17
pubmed: 19166270
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2598-603
pubmed: 20133737
Curr Med Chem. 2011;18(18):2727-42
pubmed: 21649580
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19368-73
pubmed: 23134728
PLoS One. 2010 Sep 23;5(9):e12913
pubmed: 20886116
Nat Commun. 2018 Aug 1;9(1):3014
pubmed: 30069002
J Biomol NMR. 2007 Dec;39(4):275-89
pubmed: 17955183
EMBO J. 1996 Dec 2;15(23):6541-51
pubmed: 8978681
J Biomol NMR. 2004 Feb;28(2):137-55
pubmed: 14755158
J Clin Oncol. 2011 Dec 10;29(35):4688-95
pubmed: 22025163
Nucleic Acids Res. 2015 Jul 27;43(13):6486-99
pubmed: 26101257
Nature. 2007 Jul 26;448(7152):439-44
pubmed: 17611497
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470
Methods Enzymol. 2009;462:151-75
pubmed: 19632474
Elife. 2020 Aug 03;9:
pubmed: 32744507
Curr Biol. 2002 Jul 23;12(14):1256-62
pubmed: 12176338
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):388-93
pubmed: 9892643
Nat Struct Biol. 2002 Dec;9(12):940-4
pubmed: 12434148
Mol Cell. 2008 Apr 25;30(2):203-13
pubmed: 18439899
Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10313-6
pubmed: 26110718
Int J Oncol. 2016 Mar;48(3):869-85
pubmed: 26698230
Mol Cell. 2017 Feb 2;65(3):416-431.e6
pubmed: 28157504

Auteurs

Nam Chu (N)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, United States.

Thibault Viennet (T)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.

Hwan Bae (H)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.

Antonieta Salguero (A)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, United States.

Andras Boeszoermenyi (A)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.

Haribabu Arthanari (H)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.

Philip A Cole (PA)

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH